A newsletter all about cannabis medicines, that offers patient and business perspectives written by the team at Grow.
🌱 This week, in the world of cannabis medicine:
→ Employees intro: Our wonderful Investor Relations Lead, Hannah Nommé!
→ Grow updates: There’s less than two weeks left of our crowdfund!
→ Patient perspectives: David’s* story *(pseudonym)
Hey everyone - I’m Hannah, Grow’s Investor Relations Lead!
You may have spotted my interview with Proactive in issue #3 where I discussed all the wonderful work going on at Grow and the start of our crowdfund - and now it’s great to be introducing this week’s newsletter!
My role is all about bringing together and supporting Grow’s socially-conscious shareholders! We want to do things differently here. There’s strength in numbers, and as a company working on cannabis medicine advocacy, we believe that the more people we can bring on board to share our vision, the more we can improve education and access to these life-changing medicines!
With only 13 days before our crowdfund closes, now’s the time to get involved and change the future!
In this issue, get up to date with all things Grow and read how cannabis medicines have helped one patient manage the effects of their ADHD and autism.
Since you’re now part of the gang, I’m sure I’ll see you around! I can’t wait to meet all of you potential investors and those who I haven’t already had the pleasure of speaking to! 👋
→ 📰 In the News: This week, our CEO Ben Langley spoke to Cannabis Wealth Magazine about all things Grow, covering our innovative R&D work, crowdfund and expansion plans. Read all about it here!
→ 🚨 Crowdfund update: We’ve set a new overfunding goal! We’re now looking to raise up to £3.5m, and with less than two weeks left on the campaign, it’s now or never to join one of Europe’s leading private medical cannabis companies (visit us here to find out how)🎉 A huge thank you to the 470 investors that have already signed up and joined our Grow group shareholder community 👐
Due to lingering stigma around cannabis medicines, some patients feel they can’t speak openly about their use. This is why Grow supports public information campaigns and advocacy.
“I initially started taking medical cannabis to help with my insomnia and anxiety and, after being diagnosed with ADHD and autism, I was better able to understand why and how cannabis medicines benefit so much.
The medicines greatly reduce a number of symptoms related to my conditions, including stimulation and emotional regulation, sleep, depression, and related aches and pains.
I’m now much better at handling situations that would otherwise cause me issues. It enables me to be more social and makes it easier for me to live my everyday life - and I’m much happier overall!
I’m so grateful to be able to get the medicine that helps me.”
Tips to Grow 💪
🌱 Get daily news, community chat & crowdfunding updates on Twitter & LinkedIn.
🌱 Want to knowledge share with us? You can drop us a note here.
🌱 Share with your pals and tell them about the massive positive potential of cannabis medicines.
Thanks for reading, see you next week 👋👋👋
+ + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + +
Investing involves risks, including loss of capital, illiquidity, lack of dividends and dilution, and should be done only as part of a diversified portfolio. Please read the Risk Warnings before investing. Investments should only be made by investors who understand these risks. Tax treatment depends on individual circumstances and is subject to change in future. Seedrs does not make investment recommendations to you and any investment decision should be made on the basis of the full campaign. No communications from Seedrs, through email or any other medium, should be construed as an investment recommendation.
This email has been approved as a financial promotion by Seedrs Limited.